02325 YUNKANG GROUP
- 10.960
- +0.300+2.81%
YUNKANG GROUP News
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
雲康集團：2023年度報告
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
YUNKANG GROUP(2325.HK):BACK TO NORMAL GROWTH
Yunkang Group reported 2023 revenue of RMB891.5mn, down by 76.3% YoY, primarily
Yunkang Group has received “buy” ratings from many major banks, which is optimistic about the long-term development trend of the industry
Gelonghui, April 9 | Yunkang Group recently received “buy” ratings from major banks such as CMB International and SPDB International. CMB International released a research report to maintain Yunkang Group (2325.HK)'s “buy” rating. The target price is HK$13.78. The research report mentioned that Yunkang Group's revenue in 2023 was RMB 890 million, and the non-COVID-19 business increased 26.9% year over year. Therefore, the bank believes that revenue will return to normal growth in 2024E, driven by the steady performance of core businesses such as pathological diagnosis, infectious disease testing, genetic disease diagnosis, and routine testing. As of December 31, 2023, Yunkangji
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
Read Yunkang Group (2325.HK)'s 2023 performance report in one picture
On March 25, Yunkang Group (2325.HK) announced its 2023 results announcement. In 2023, the company recorded revenue of 892 million yuan (RMB, same unit), an increase of 31.5% compared with 2019. As of December 31, 2023, Yunkang's customers spread across 31 provinces and autonomous regions, and more than 200 cities. It has built 416 medical consortium on-site diagnosis centers, 1,500+ medical and non-medical institutions, 3,900 medical and non-medical institutions, with more than 3,000 testing projects, and the company has more than 800 doctors and medical technicians. underneath
Yunkang Group (2325.HK): 2023 results were pressured by COVID-19 test clearance and receivables impairment, routine testing revenue +27% YoY
The company's 2023 performance is under pressure, mainly due to 1) clearance of COVID-19 testing requirements within 2023 (vs COVID-19 revenue accounts for about 80%); 2) provision for impairment of COVID-19 accounts receivable. We expect the company to remain profitable in the short term
Yunkang Swings to Loss in 2023; Recommends Dividend
Yunkang Group (HKG:2325) recorded a net loss of 101.9 million yuan for the year ended December 2023, as opposed to a profit of 373.9 million yuan in the preceding year, according to a Monday filing wi
YUNKANG GROUP To Go Ex-Dividend On July 4th, 2024 With 0.02 HKD Dividend Per Share
March 26th - $YUNKANG GROUP(02325.HK)$ is trading ex-dividend on July 4th, 2024. Shareholders of record on July 5th, 2024 will receive 0.02 HKD dividend per share. The ex-dividend date is July 4th
Press Release: Yunkang Announces 2023 Annual Results, Revenue Reaches RMB892 Million
HONG KONG, March 25, 2024 /PRNewswire/ -- Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2023 (the "Reporting Period").
Yunkang Group (02325) will pay a final dividend of HK$0.02 per share
Yunkang Group (02325) announced that the company will distribute final shares for the year ended December 31, 2023...
Yunkang Group (02325) announced annual results. Shareholders' losses amounted to 102 million yuan year-on-year profit and loss
Yunkang Group (02325) announced its annual results for the year ended December 31, 2023. The group reaped benefits, people...
YUNKANG GROUP: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Yunkang Group (02325.HK) held a board meeting on March 25 to approve annual results
Gelonghui, March 13, 丨 Yunkang Group (02325.HK) announced that the company will hold a board meeting on March 25, 2024 (Monday) to (among others) approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and consider payment of a final dividend (if any).
雲康集團：董事會會議日期
Yunkang Group Expects a Loss of Up to 130 Million Yuan for Full Year 2023
Yunkang Group (HKG:2325) expects a net loss of 90 million yuan to 130 million yuan for the year ended Dec. 31, 2023, compared with a net profit of 373.9 million yuan in the prior year, a Hong Kong bou
Yunkang Group (02325.HK) issued an announcement. The routine testing business achieved healthy and steady growth, and the net cash from operating activities improved markedly
Gelonghui, March 5, 丨 Yunkang Group (02325.HK) announced that the Group expects to record a net loss of between RMB 90 million and RMB 130 million for the year ended December 31, 2023, while a profit of RMB 373.9 million was recorded for the year ended 31 December 2022. The expected change in profit to loss is mainly due to: (i) During the reporting period, the Group's overall diagnostic service revenue declined significantly compared to the same period last year due to the decline in demand for phased testing and screening across the country, resulting in a decrease in the Group's profit. However, without considering the impact of the national phased testing and screening business, it was collected during the reporting period
Analysis
Price Target
No Data
